EAM Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

EAM Investors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-79,905	Closed	-$2.57M	–	393
2023 Q1	$2.57M	Buy	+79,905	New	+$2.49M	0.51%	63
2022 Q4	–	Sell	-94,413	Closed	-$2.55M	–	354
2022 Q3	$2.55M	Buy	+94,413	New	+$1.92M	0.55%	57
2020 Q4	–	Sell	-42,537	Closed	-$1.07M	–	404
2020 Q3	$1.07M	Buy	42,537 +10,985	+35%	+$288K	0.25%	187
2020 Q2	$770K	Sell	31,552 -53,750	-63%	-$1.06M	0.17%	220
2020 Q1	$1.26M	Sell	85,302 -20,127	-19%	-$416K	0.39%	122
2019 Q4	$1.71M	Buy	+105,429	New	+$1.64M	0.38%	108
2018 Q2	–	Sell	-113,096	Closed	-$3.48M	–	364
2018 Q1	$3.48M	Buy	113,096 +5,763	+5%	+$185K	0.58%	42
2017 Q4	$3.84M	Buy	107,333 +34,815	+48%	+$1,000K	0.69%	21
2017 Q3	$2M	Buy	72,518 +38,621	+114%	+$936K	0.27%	194
2017 Q2	$895K	Buy	+33,897	New	+$756K	0.15%	210
2016 Q1	–	Sell	-102,800	Closed	-$3.51M	–	353
2015 Q4	$3.51M	Buy	+102,800	New	+$3.56M	0.46%	75
2014 Q3	–	Sell	-52,668	Closed	-$1.79M	–	363
2014 Q2	$1.79M	Buy	+52,668	New	+$1.65M	0.34%	86

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's RVNC Position: Q2 2023 in Review

EAM Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 79,905 shares — an estimated $2.57M sold.

EAM Investors first reported a position in RVNC in Q2 2014 and held it in 12 quarters. The position peaked at $3.84M in Q4 2017. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

EAM Investors reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
EAM Investors sold 79,905 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $2.57M.
EAM Investors first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 12 quarters.
EAM Investors's Revance Therapeutics, Inc. position peaked at $3.84M in Q4 2017.
215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.